Literature DB >> 26711783

Oncogenic roles of carbonic anhydrase 8 in human osteosarcoma cells.

Tze-Kai Wang1, Yu-Ming Lin2, Che-Min Lo1, Chih-Hsin Tang3, Chieh-Lin Jerry Teng4, Wei-Ting Chao1,5, Min Huan Wu5,6, Chin-San Liu7, Mingli Hsieh8,9.   

Abstract

Carbonic anhydrase 8 (CA8), a member of the carbonic anhydrase family, is one of the three isozymes that do not catalyze the reversible hydration of carbon dioxide due to the lack of one important histidine. In the present study, we observed increased expression of CA8 in more aggressive types of human osteosarcoma (OS) cells and found that CA8 expression is correlated with disease stages, such that more intense expression occurs in the disease late stage. We also demonstrated that overexpression of CA8 in human OS (HOS) cells significantly increased cell proliferation both in vitro and in vivo. Downregulated CA8 sensitized cells to apoptotic stress induced by staurosporine and cisplatin, suggesting a specific role of CA8 to protect cells from stresses. In addition, downregulation of CA8 in HOS cells reduced cell invasion and colony formation ability in soft agar and further decreased matrix metalloproteinase 9 and focal adhesion kinase expression, indicating that CA8 might facilitate cancer cell invasion via the activation of FAK-MMP9 signaling. Interestingly, HOS cells with CA8 knockdown showed a significant decrease in glycolytic activity and cell death under glucose withdrawal, further indicating that CA8 may be involved in regulating aerobic glycolysis and enhancing cell viability. Knockdown of CA8 significantly decreased phosphorylated Akt expression suggesting that the oncogenic role of CA8 may be mediated by the regulation of Akt activation through p-Akt induction. Importantly, the inhibition of glycolysis by 2-deoxyglucose sensitized CA8 HOS-CA8-myc cells to cisplatin treatment under low glucose condition, highlighting a new therapeutic option for OS cancer.

Entities:  

Keywords:  2-Deoxy-D-glucose; Carbonic anhydrase 8; Cell migration; Cisplatin; Osteosarcoma; Proliferation

Mesh:

Substances:

Year:  2015        PMID: 26711783     DOI: 10.1007/s13277-015-4661-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  69 in total

1.  On respiratory impairment in cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-08-10       Impact factor: 47.728

2.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark Krailo; Eugenie S Kleinerman; Donna Betcher; Mark L Bernstein; Ernest Conrad; William Ferguson; Mark Gebhardt; Allen M Goorin; Michael B Harris; John Healey; Andrew Huvos; Michael Link; Joseph Montebello; Helen Nadel; Michael Nieder; Judith Sato; Gene Siegal; Michael Weiner; Robert Wells; Lester Wold; Richard Womer; Holcombe Grier
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

3.  Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling.

Authors:  Kelai Wang; Yan Zhuang; Chunlan Liu; Yang Li
Journal:  Arch Biochem Biophys       Date:  2012-07-20       Impact factor: 4.013

4.  FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway.

Authors:  Vijayalakshmi Thamilselvan; David H Craig; Marc D Basson
Journal:  FASEB J       Date:  2007-02-22       Impact factor: 5.191

5.  The metastasectomy and timing of pulmonary metastases on the outcome of osteosarcoma patients.

Authors:  Yu-Min Huang; Chun-Han Hou; Sheng-Mou Hou; Rong-Sen Yang
Journal:  Clin Med Oncol       Date:  2009-09-14

6.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

7.  Cardiovascular performance and oxyhemoglobin dissociation after acetazolamide in metabolic alkalosis.

Authors:  P Berthelsen
Journal:  Intensive Care Med       Date:  1982       Impact factor: 17.440

8.  Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases.

Authors:  A H Aljubran; A Griffin; M Pintilie; M Blackstein
Journal:  Ann Oncol       Date:  2009-01-19       Impact factor: 32.976

Review 9.  Targeting glucose metabolism for cancer therapy.

Authors:  Robert B Hamanaka; Navdeep S Chandel
Journal:  J Exp Med       Date:  2012-02-13       Impact factor: 14.307

10.  miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.

Authors:  Yong Zhou; Zufa Huang; Song Wu; Xiaofang Zang; Min Liu; Jian Shi
Journal:  J Exp Clin Cancer Res       Date:  2014-01-27
View more
  3 in total

1.  Altered glucose metabolism and its association with carbonic anhydrase 8 in Machado-Joseph Disease.

Authors:  Guan-Yu Lin; Chung-Yung Ma; Li-Chung Kuo; Benjamin Y Hsieh; Hanbing Wang; Chin-San Liu; Mingli Hsieh
Journal:  Metab Brain Dis       Date:  2022-04-30       Impact factor: 3.655

2.  Carbonic Anhydrase VIII (CAVIII) Gene Mediated Colorectal Cancer Growth and Angiogenesis through Mediated miRNA 16-5p.

Authors:  Mingli Hsieh; Pei-Ju Huang; Pei-Yu Chou; Shih-Wei Wang; Hsi-Chi Lu; Wei-Wen Su; Yuan-Chiang Chung; Min-Huan Wu
Journal:  Biomedicines       Date:  2022-04-29

3.  Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors.

Authors:  Sini L Karjalainen; Hannu K Haapasalo; Ashok Aspatwar; Harlan Barker; Seppo Parkkila; Joonas A Haapasalo
Journal:  BMC Cancer       Date:  2018-05-23       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.